WNT2 and esophageal squamous cell carcinoma: In addition, in mice ESCC and colorectal cancer homologous tumor models, the anti-WNT2 monoclonal antibody greatly restored anti-tumour T-cell responses and enhanced the therapeutic effect of anti-PD-1 treatment.